To the Editor The randomized clinical trial (RCT) by Uranga et al1 in a recent issue of JAMA Internal Medicine aimed to validate the algorithm on antibiotic duration for community-acquired pneumonia (CAP) recommended by the 2007 guidelines.2 We congratulate Uranga et al on this study. It examines a timely and important issue: that limiting the duration of therapy is an understudied and underused aspect of antimicrobial stewardship. However, we have some concerns about the study’s design and conduct.
Albrich WC, Huttner BD, Huttner A. Validation of IDSA/ATS Algorithm for Duration of Pneumonia Therapy. JAMA Intern Med. 2017;177(2):283-284. doi:10.1001/jamainternmed.2016.8574